Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5

被引:19
|
作者
Tamura, Tomokazu [1 ,2 ]
Yamasoba, Daichi [3 ,4 ]
Oda, Yoshitaka [5 ]
Ito, Jumpei [3 ]
Kamasaki, Tomoko [6 ,7 ,8 ]
Nao, Naganori [2 ,9 ,10 ]
Hashimoto, Rina [11 ]
Fujioka, Yoichiro [6 ,7 ,8 ]
Suzuki, Rigel [1 ,2 ]
Wang, Lei [5 ,12 ]
Ito, Hayato [1 ]
Kashima, Yukie [13 ]
Kimura, Izumi [3 ]
Kishimoto, Mai [14 ]
Tsuda, Masumi
Sawa, Hirofumi [2 ,9 ,10 ,14 ,15 ]
Yoshimatsu, Kumiko [16 ]
Yamamoto, Yuki [17 ]
Nagamoto, Tetsuharu [17 ]
Kanamune, Jun [17 ]
Suzuki, Yutaka [13 ]
Ohba, Yusuke [6 ,7 ,8 ]
Tabata, Kaori
Yokota, Isao [18 ]
Matsuno, Keita [2 ,10 ,15 ,19 ]
Takayama, Kazuo [8 ,9 ,11 ]
Tanaka, Shinya [5 ,12 ]
Sato, Kei [3 ,20 ,21 ,22 ,23 ,24 ,25 ]
Fukuhara, Takasuke [1 ,2 ,8 ,26 ]
机构
[1] Hokkaido Univ, Dept Microbiol & Immunol, Fac Med, Sapporo, Japan
[2] Hokkaido Univ, Inst Vaccine Res & Dev, HU IVReD, Sapporo, Japan
[3] Univ Tokyo, Inst Med Sci, Div Syst Virol, Dept Microbiol & Immunol, Tokyo, Japan
[4] Kobe Univ, Fac Med, Kobe, Japan
[5] Hokkaido Univ, Dept Canc Pathol, Fac Med, Sapporo, Japan
[6] Hokkaido Univ, Dept Cell Physiol, Fac Med, Sapporo, Japan
[7] Hokkaido Univ, Global Stn Biosurfaces & Drug Discovery, Sapporo, Japan
[8] Japan Agcy Med Res & Dev, AMED CREST, Tokyo, Japan
[9] Hokkaido Univ, Int Inst Zoonosis Control, Div Int Res Promot, Sapporo, Japan
[10] Hokkaido Univ, One Hlth Res Ctr, Sapporo, Hokkaido, Japan
[11] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan
[12] Hokkaido Univ, Inst Chem React Design & Discovery WPI ICReDD, Sapporo, Japan
[13] Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Japan
[14] Hokkaido Univ, Int Inst Zoonosis Control, Div Mol Pathobiol, Sapporo, Japan
[15] Hokkaido Univ, Int Inst Zoonosis Control, Int Collaborat Unit, Sapporo, Japan
[16] Hokkaido Univ, Inst Med Genet, Sapporo, Japan
[17] HiLung Inc, Kyoto, Japan
[18] Hokkaido Univ, Dept Biostat, Fac Med, Sapporo, Japan
[19] Hokkaido Univ, Int Inst Zoonosis Control, Div Risk Anal & Management, Sapporo, Japan
[20] Univ Tokyo, Grad Sch Med, Tokyo, Japan
[21] Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba, Japan
[22] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Tokyo, Japan
[23] Univ Tokyo, Inst Med Sci, Int Vaccine Design Ctr, Tokyo, Japan
[24] Kumamoto Univ, Collaborat Unit Infect, Joint Res Ctr Human Retrovirus Infect, Kumamoto, Japan
[25] CREST, Japan Sci & Technol Agcy, Kawaguchi, Japan
[26] Osaka Univ, Microbial Dis Res Inst, Lab Virus Control, Suita, Japan
关键词
CELLS;
D O I
10.1038/s42003-023-05081-w
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The virological and pathological features of Omicron subvariants are compared in in vitro cellular and airway-on-a-chip and in vivo hamster models. The unremitting emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants necessitates ongoing control measures. Given its rapid spread, the new Omicron subvariant BA.5 requires urgent characterization. Here, we comprehensively analyzed BA.5 with the other Omicron variants BA.1, BA.2, and ancestral B.1.1. Although in vitro growth kinetics of BA.5 was comparable among the Omicron subvariants, BA.5 was much more fusogenic than BA.1 and BA.2. Airway-on-a-chip analysis showed that, among Omicron subvariants, BA.5 had enhanced ability to disrupt the respiratory epithelial and endothelial barriers. Furthermore, in our hamster model, in vivo pathogenicity of BA.5 was slightly higher than that of the other Omicron variants and less than that of ancestral B.1.1. Notably, BA.5 gains efficient virus spread compared with BA.1 and BA.2, leading to prompt immune responses. Our findings suggest that BA.5 has low pathogenicity compared with the ancestral strain but enhanced virus spread /inflammation compared with earlier Omicron subvariants.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
    Kumar, Sanjeev
    Patel, Anamika
    Lai, Lilin
    Chakravarthy, Chennareddy
    Valanparambil, Rajesh
    Reddy, Elluri Seetharami
    Gottimukkala, Kamalvishnu
    Davis-Gardner, Meredith E.
    Edara, Venkata Viswanadh
    Linderman, Susanne
    Nayak, Kaustuv
    Dixit, Kritika
    Sharma, Pragati
    Bajpai, Prashant
    Singh, Vanshika
    Frank, Filipp
    Cheedarla, Narayanaiah
    Verkerke, Hans P.
    Neish, Andrew S.
    Roback, John D.
    Mantus, Grace
    Goel, Pawan Kumar
    Rahi, Manju
    Davis, Carl W.
    Wrammert, Jens
    Godbole, Sucheta
    Henry, Amy R.
    Douek, Daniel C.
    Suthar, Mehul S.
    Ahmed, Rafi
    Ortlund, Eric
    Sharma, Amit
    Murali-Krishna, Kaja
    Chandele, Anmol
    [J]. SCIENCE ADVANCES, 2022, 8 (40):
  • [22] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
    Wilhelm, Alexander
    Widera, Marek
    Grikscheit, Katharina
    Toptan, Tuna
    Schenk, Barbara
    Pallas, Christiane
    Metzler, Melinda
    Kohmer, Niko
    Hoehl, Sebastian
    Marschalek, Rolf
    Herrmann, Eva
    Helfritz, Fabian A.
    Wolf, Timo
    Goetsch, Udo
    Ciesek, Sandra
    [J]. EBIOMEDICINE, 2022, 82
  • [23] Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
    Li, Mingxi
    Ren, Yifei
    Aw, Zhen Qin
    Chen, Bo
    Yang, Ziqing
    Lei, Yuqing
    Cheng, Lin
    Liang, Qingtai
    Hong, Junxian
    Yang, Yiling
    Chen, Jing
    Wong, Yi Hao
    Wei, Jing
    Shan, Sisi
    Zhang, Senyan
    Ge, Jiwan
    Wang, Ruoke
    Dong, Jay Zengjun
    Chen, Yuxing
    Shi, Xuanling
    Zhang, Qi
    Zhang, Zheng
    Chu, Justin Jang Hann
    Wang, Xinquan
    Zhang, Linqi
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [24] Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
    Vatteroni, Maria Linda
    Capria, Anna-Lisa
    Spezia, Pietro Giorgio
    Frateschi, Susi
    Pistello, Mauro
    [J]. LANCET MICROBE, 2022, 3 (07): : E478 - E478
  • [25] Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
    Mingxi Li
    Yifei Ren
    Zhen Qin Aw
    Bo Chen
    Ziqing Yang
    Yuqing Lei
    Lin Cheng
    Qingtai Liang
    Junxian Hong
    Yiling Yang
    Jing Chen
    Yi Hao Wong
    Jing Wei
    Sisi Shan
    Senyan Zhang
    Jiwan Ge
    Ruoke Wang
    Jay Zengjun Dong
    Yuxing Chen
    Xuanling Shi
    Qi Zhang
    Zheng Zhang
    Justin Jang Hann Chu
    Xinquan Wang
    Linqi Zhang
    [J]. Nature Communications, 13
  • [26] Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection
    Jang, Eun Jung
    Choe, Young June
    Kim, Ryu Kyung
    Lee, Sangwon
    Park, Seon Kyeong
    Park, Young-Joon
    [J]. JAMA NETWORK OPEN, 2023, 6 (03) : E232578
  • [27] Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
    Xiaoyu Ma
    Yanqun Wang
    Yuanzhu Gao
    Yiliang Wang
    An Yan
    Jiantao Chen
    Lu Zhang
    Peiyi Wang
    Jincun Zhao
    Zheng Liu
    [J]. Signal Transduction and Targeted Therapy, 8
  • [28] Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
    Ma, Xiaoyu
    Wang, Yanqun
    Gao, Yuanzhu
    Wang, Yiliang
    Yan, An
    Chen, Jiantao
    Zhang, Lu
    Wang, Peiyi
    Zhao, Jincun
    Liu, Zheng
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [29] Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England
    Elliott, Paul
    Eales, Oliver
    Steyn, Nicholas
    Tang, David
    Bodinier, Barbara
    Wang, Haowei
    Elliott, Joshua
    Whitaker, Matthew
    Atchison, Christina
    Diggle, Peter J.
    Page, Andrew J.
    Trotter, Alexander J.
    Ashby, Deborah
    Barclay, Wendy
    Taylor, Graham
    Ward, Helen
    Darzi, Ara
    Cooke, Graham S.
    Donnelly, Christl A.
    Chadeau-Hyam, Marc
    [J]. SCIENCE, 2022, 376 (6600) : 1432 - +
  • [30] Viral load of SARS-CoV-2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5
    Takatsuki, Yuna
    Takahashi, Yuta
    Nakajima, Jun
    Iwasaki, Yumi
    Nagano, Katsutoshi
    Tani-Sassa, Chihiro
    Yuasa, Sonoka
    Kanehira, Saki
    Sonobe, Kazunari
    Nukui, Yoko
    Takeuchi, Hiroaki
    Tanimoto, Kousuke
    Tanaka, Yukie
    Kimura, Akinori
    Ichimura, Naoya
    Tohda, Shuji
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (02)